- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Elevation Oncology Inc (ELEV)
Elevation Oncology Inc stock price live, this page displays NASDAQ ELEV stock exchange data. View the ELEV premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Elevation Oncology Inc real time stock price chart below.
What Is the Elevation Oncology Inc Stock Price Today?
The Elevation Oncology Inc stock price today is 0.283.
What Is the Stock Symbol for Elevation Oncology Inc?
The stock symbol for Elevation Oncology Inc is "ELEV."
What Stock Exchange Does Elevation Oncology Inc Trade On?
Elevation Oncology Inc is listed and trades on the NASDAQ stock exchange.
Is Elevation Oncology Inc a Good Stock to Buy?
Determining whether Elevation Oncology Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ELEV quote. (ISIN: US28623U1016)
What Is the Elevation Oncology Inc Stock Price Today?
The Elevation Oncology Inc stock price today is 0.283.
What Is the Stock Symbol for Elevation Oncology Inc?
The stock symbol for Elevation Oncology Inc is "ELEV."
What Stock Exchange Does Elevation Oncology Inc Trade On?
Elevation Oncology Inc is listed and trades on the NASDAQ stock exchange.
Is Elevation Oncology Inc a Good Stock to Buy?
Determining whether Elevation Oncology Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ELEV quote. (ISIN: US28623U1016)
NASDAQ
Currency in USD
0.283
-0.017(-5.67%)
Closed·
After Hours
0.272-0.011(-3.887%)
·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.272
0.306
52 wk Range
0.221
4.330
ELEV Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
ELEV is not included in our AI-picked strategies. See which stocks are.
Review Strategies
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.2720.306
52 wk Range
0.2214.330
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ELEV Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
1.020
Upside
+260.42%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
3 analysts have revised their earnings downwards for the upcoming period
Elevation Oncology Inc Company Profile
Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. It’s lead candidate is EO-3021, an antibody-drug conjugate (ADC) comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload that is in Phase 1 clinical trial as a monotherapy and in combinations with dostarlimab, a PD-1 inhibitor, and ramucirumab, a VEGFR2 inhibitor, in patients with advanced, unresectable, or metastatic gastric/gastroesophageal junction solid tumors. The company is also developing EO-1022, an ADC containing seribantumab, a fully human immunoglobulin G2 (IgG2) anti-HER3 mAb, and an MMAE payload, with glycan site-specific conjugation for the treatment of patients with HER3-expressing solid tumors, including breast cancer, non-small cell lung cancer, and other solid tumors. It has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021 for the treatment of cancer. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.
Elevation Oncology Inc SWOT Analysis
Promising ADC Pipeline | Elevation Oncology's lead candidate EO-3021 shows best-in-class efficacy for gastric cancers, with a 43% objective response rate in Claudin-selected patients |
Safety Advantage | EO-3021's favorable safety profile, particularly the absence of significant hematological adverse events, positions it well for potential combination therapies |
Strategic Combinations | Explore Elevation's innovative approach to combining EO-3021 with existing treatments, potentially expanding its market reach in first and second-line settings |
Financial Outlook | With a $111M cash balance and analyst price targets ranging from $6 to $7, Elevation Oncology is positioned to fund operations through key clinical milestones into 2026 |
Compare ELEV to Peers and Sector
Metrics to compare | ELEV | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipELEVPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.3x | −3.4x | −0.5x | |
PEG Ratio | −0.03 | 0.00 | 0.00 | |
Price/Book | 0.4x | 1.8x | 2.6x | |
Price / LTM Sales | - | 25.6x | 3.0x | |
Upside (Analyst Target) | 253.4% | 230.1% | 53.7% | |
Fair Value Upside | Unlock | 3.2% | 8.4% | Unlock |
Analyst Ratings
3 Buy
5 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 1.020
(+260.42% Upside)
Earnings
Latest Release
May 14, 2025
EPS / Forecast
-0.24 / -0.20
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Is the Elevation Oncology (ELEV) Stock Price Today?
The Elevation Oncology stock price today is 0.28
What Stock Exchange Does Elevation Oncology Trade On?
Elevation Oncology is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Elevation Oncology?
The stock symbol for Elevation Oncology is "ELEV."
What Is the Elevation Oncology Market Cap?
As of today, Elevation Oncology market cap is 16.73M.
What Is Elevation Oncology's Earnings Per Share (TTM)?
The Elevation Oncology EPS (TTM) is -0.81.
When Is the Next Elevation Oncology Earnings Date?
Elevation Oncology will release its next earnings report on Aug 06, 2025.
From a Technical Analysis Perspective, Is ELEV a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.